Physician profile
Laura Borsa
NPI 1477234201
$304.83
in general payments reported to CMS, 2019-2025
11 companies · $34.14 in 2025
The $34.14 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $73.07 · 2024: $198 · 2025: $34.14.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $305.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $304.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $82.26 | 2023-2024 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $30.03 | 2023-2024 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $28.92 | 2024 | Abilify Asimtufii |
| Abbvie INC. | $28.08 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $23.96 | 2024 | Austedo Xr |
| Neurocrine Biosciences, INC. | $23.63 | 2024 | Ingrezza |
| Corcept Therapeutics | $21.20 | 2024 | Korlym |
| Dexcom, INC. | $20.13 | 2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $18.48 | 2023 | Mounjaro |
| Alkermes, INC. | $14.13 | 2024 | Aristada, Lybalvi |
| Gilead Sciences, INC. | $14.01 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Borsa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.